CClinicalTrials.gg
Not yet recruitingNCT07865884SIDEMARAUpdated Oct 8, 2026

Tissue Validation of Mammographic Breast Arterial Calcification in Mastectomy Specimens (SIDEMARA)

An observational study in Breast Cancer, Vascular Calcification and Coronary Artery Calcification, sponsored by Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital. Not yet recruiting. Open to female participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital · Observational

Updated Oct 8, 2026Newly registeredGo to Updates ↓
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
40 Years and older
Sex
Female
01

Study summary

Breast arterial calcification (BAC) is a common incidental finding on screening mammograms and has been associated with cardiovascular disease in women. However, every study in this field has been imaging-based. The accuracy of mammography for detecting breast arterial calcification has only ever been measured against another radiologist reading the same mammogram, never against the tissue itself. As a result, it is not known how much calcification mammography misses, nor whether what it shows represents medial (Monckeberg-type) calcification or true atherosclerosis.

This prospective observational study compares mammographic BAC with the histopathology of breast arteries obtained from mastectomy specimens. Women aged 40 years and older undergoing upfront mastectomy, without neoadjuvant therapy, for invasive breast cancer or ductal carcinoma in situ will be enrolled consecutively. Additional tissue blocks will be taken from tumour-free areas of the specimen and examined with von Kossa and elastic van Gieson stains to determine whether arterial calcification is present and whether it lies in the media or the intima. These findings will be compared with the preoperative mammogram, which is read independently and blind to the pathology result.

As a secondary and exploratory objective, coronary artery calcification will be scored from staging computed tomography images already acquired for cancer staging.

No additional tests, imaging, radiation exposure or blood sampling will be performed for the purposes of this study, and the surgical procedure will not be altered in any way.

Read the detailed description

This is a single-centre, prospective, cross-sectional diagnostic accuracy study. There is no randomisation, no control group and no intervention.

Rationale. Artificial-intelligence-based quantification of BAC in a cohort of 123,762 women has shown a dose-response relationship with major adverse cardiovascular events and incremental prognostic value over conventional risk scores. Systematic reviews support this association. Two questions remain unresolved. First, BAC is thought to be located in the tunica media rather than the tunica intima, making it medial arterial calcification rather than atherosclerosis, but direct histopathological verification in breast tissue is very limited. Second, and more critically, the field has no external reference standard: reported sensitivity values measure agreement with a human reader, not with tissue.

Specimen Handling The operation is not modified for the study. The specimen is oriented in theatre with two sutures (single suture superior, double suture lateral). In addition to diagnostic sampling, six research blocks are taken from macroscopically tumour-free areas: two from the upper outer quadrant, one from the upper inner quadrant, one from the lower quadrants, one from deep tissue adjacent to the prepectoral fascia and one from the central or retroareolar region. If there is any doubt about the adequacy of tissue for diagnosis, no additional block is taken; correct diagnosis always takes precedence.

Histopathological Assessment A stepwise staining algorithm is used: routine haematoxylin and eosin on all six blocks; von Kossa on blocks containing arteries of assessable calibre; elastic van Gieson on cases with calcification, to determine the layer involved. Presence, location (medial or intimal), circumferential extent and a 0-3 ordinal severity score are recorded, together with morphometric measurements made in free software. Intimal lesions are graded 0-4 using predefined morphological criteria, with grade 2 or above classified as atherosclerotic change. No additional immunohistochemistry is performed.

Mammographic Assessment The existing preoperative digital mammogram is read primarily in the mediolateral oblique projection. Presence of BAC, a 0-3 ordinal severity score and an estimated calcification area in square millimetres are recorded.

Coronary artery calcification.Ordinal scoring is performed on staging PET-CT or thoracic CT images already acquired. The reader is a radiologist or nuclear medicine physician who is not among the mammography readers of this study. Cases without thoracic imaging, and those with previous coronary revascularisation, are excluded from this sub-analysis but remain in the primary analysis.

Blinding The pathologist is blind to mammographic and coronary findings. The mammography reader is blind to histopathology and coronary findings. The coronary calcification reader is blind to histopathology, mammography and the patient's clinical cardiovascular history. Twenty per cent of cases are re-read by independent second readers to measure inter-observer agreement.

Statistics. With histopathology as the reference standard, sensitivity, specificity and predictive values of mammography are estimated with 95 per cent confidence intervals by the Wilson method. Because this is a preliminary study, the primary inference is drawn from the upper limit of the confidence interval rather than from the point estimate. Reporting follows the STARD guideline.

02

Conditions studied

  • Breast Cancer
  • Vascular Calcification
  • Coronary Artery Calcification
  • Atherosclerosis Cardiovascular Disease

Keywords

  • breast cancer
  • vascular calcification
  • breast arterial calcification
  • coronary artery calcification
  • atherosclerosis
03

In context

Breast Neoplasms

12,544 studies on the registry are indexed under Breast Neoplasms; 2,892 are open to participants now.

This study's planned enrollment of 100 is below the median of 184 across 2,642 observational studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital is the lead sponsor of 39 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Consecutive women undergoing upfront mastectomy for breast cancer at a single tertiary training and research hospital in Istanbul, Turkey.

Inclusion criteria

  • Female
  • Aged 40 years or older
  • Scheduled for mastectomy for invasive breast carcinoma or ductal carcinoma in situ. All mastectomy types are eligible: simple, modified radical, skin-sparing, nipple-sparing and subcutaneous
  • Full-field digital mammogram performed within 6 months before surgery and available for review
  • Written informed consent

Exclusion criteria

Exclusion Criteria:

  • Neoadjuvant chemotherapy or neoadjuvant endocrine therapy
  • Previous surgery or radiotherapy to the ipsilateral breast
  • Previous radiotherapy to the thoracic region
  • Breast implant
  • Inflammatory breast carcinoma
  • Male breast cancer
  • Chronic haemodialysis treatment
  • Known hereditary disorder of vascular calcification
  • Only analogue film mammography available
  • Mammographic images not assessable
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Women undergoing upfront mastectomy

    Women aged 40 years and older undergoing mastectomy without neoadjuvant therapy for invasive breast carcinoma or ductal carcinoma in situ, with a preoperative digital mammogram available for review.

06

What researchers measure

Primary outcomes

  1. Sensitivity of mammography for histopathologically confirmed medial arterial calcification

    Proportion of cases with histopathologically confirmed medial calcification of breast arteries in which breast arterial calcification is also reported on the preoperative mammogram. Histopathology serves as the reference standard. Reported with a 95 percent confidence interval calculated by the Wilson method. The primary inference is drawn from the upper limit of this interval.

    Time frame: From surgery to completion of histopathological assessment, up to 2 months per participant

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

1 registry update since Sep 25, 2026
Registered
First appeared on the registry. No changes since
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07865884
Lead sponsor
Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital
Responsible party
Adnan Gundogdu (MD, Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital) — Principal investigator
First posted
Oct 8, 2026
Start date
Oct 15, 2026 (estimated)
Primary completion
Nov 1, 2027 (estimated)
Completion
Dec 30, 2027 (estimated)
Last update
Oct 8, 2026

Study contacts

Adnan Gündoğdu, Medical Doctor
Contact
adnangundogdu89@gmail.com
+90 5367173909

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion